市場調查報告書
商品編碼
1463640
南美洲和中美洲主動脈瓣置換設備市場預測至 2030 年 - 區域分析 - 按產品、手術和最終用戶South & Central America Aortic Valve Replacement Devices Market Forecast to 2030 - Regional Analysis - by Product, Surgery, and End User |
南美洲和中美洲主動脈瓣置換裝置市場預計將從2022年的3.6563億美元CAGR到2030年的8.7641億美元。
主動脈瓣置換裝置的進步推動了南美洲和中美洲主動脈瓣置換裝置市場
微創手術技術(MIS)的發展,例如經導管主動脈瓣置換術(TAVR),使主動脈瓣狹窄(AS)的治療現代化。經導管主動脈瓣置換術比傳統的心臟直視手術侵入性更小,使得不適合手術的高風險患者能夠接受治療。此外,材料和設計的發展導致了更堅固和生物相容性主動脈瓣置換術的開發,這改善了患者的治療結果並降低了併發症的風險。
以下提到了主動脈瓣置換裝置領域的一些技術進步:
2023 年 1 月,雅培 (Abbott) 的 Navitor 經導管主動脈瓣植入 (TAVI) 系統獲得 FDA 批准,用於治療心臟直視手術高風險的嚴重主動脈瓣狹窄患者。 Navitor 是該公司廣泛的經導管結構性心臟產品組合的最新成員,為醫生和患者提供一系列嚴重心臟病的微創治療選擇。
2021 年 9 月,雅培的 Epic Plus 和 Epic Plus Supra 支架組織瓣膜獲得 FDA 批准,以改善主動脈瓣或二尖瓣疾病患者的治療選擇。透過這款新設備,雅培擴展了其 Epic 手術瓣膜平台。
因此,技術進步正在主動脈瓣置換裝置市場創造利潤豐厚的機會。
南美洲和中美洲主動脈瓣置換設備市場概述
南美洲和中美洲主動脈瓣置換裝置市場分為巴西、阿根廷以及南美洲和中美洲其他地區。由於主動脈瓣狹窄盛行率激增,各政府組織為提高人們對瓣膜置換手術的認知而採取的舉措,預計該地區的市場將會成長。
南美洲及中美洲主動脈瓣置換設備市場收入及 2030 年預測(百萬美元)
南美洲和中美洲主動脈瓣置換設備市場細分
南美洲和中美洲主動脈瓣置換裝置市場分為產品、手術、最終用戶和國家。
根據產品,南美洲和中美洲主動脈瓣置換裝置市場分為無縫線瓣膜和機械瓣膜。到 2022 年,無縫線瓣膜將在南美洲和中美洲主動脈瓣置換設備市場中佔據更大佔有率。
根據手術,南美洲和中美洲主動脈瓣置換裝置市場分為微創手術和開放性手術。到 2022 年,微創手術細分市場將在南美洲和中美洲主動脈瓣置換設備市場中佔據更大佔有率。
根據最終用戶,南美洲和中美洲主動脈瓣置換設備市場分為醫院和診所、門診手術中心等。到 2022 年,醫院和診所細分市場將佔據南美洲和中美洲主動脈瓣置換設備最大的市場佔有率。
根據國家/地區,南美洲和中美洲主動脈瓣置換裝置市場分為巴西、阿根廷以及南美洲和中美洲其他地區。 2022 年,巴西在南美洲和中美洲主動脈瓣置換設備市場佔有率中佔據主導地位。
雅培實驗室、美敦力公司、波士頓科學公司、LivaNova Plc、Edwards Lifesciences Corp、Braile Biomedica Industry, Commerce and Representations Ltd、Artivion Inc、啟明醫療科技杭州有限公司和 Labcor Laboratorios Ltda。 ,是主動脈瓣置換設備市場上的一些領先公司。
The South & Central America aortic valve replacement devices market is expected to grow from US$ 365.63 million in 2022 to US$ 876.41 million by 2030. It is estimated to grow at a CAGR of 11.5% from 2022 to 2030.
Advancements in Aortic Valve Replacement Devices Fuels South & Central America Aortic Valve Replacement Devices Market
The development of minimally invasive surgical techniques (MIS), such as transcatheter aortic valve replacement (TAVR), has modernized the treatment of aortic stenosis (AS). Transcatheter aortic valve replacement is less invasive than traditional open-heart surgery, making it possible for high-risk patients who may not have been eligible for surgery to receive treatment. Moreover, developments in materials and design have led to the development of stronger and biocompatible aortic valve replacements, which have improved patient outcomes and reduced the risk of complications.
A few technological advancements by the players in the aortic valve replacement devices are mentioned below:
In January 2023, Abbott received FDA approval for the Navitor transcatheter aortic valve implantation (TAVI) system to treat people with severe aortic stenosis at high risk of open-heart surgery. Navitor is the latest addition to the company's extensive transcatheter structural heart portfolio, which offers physicians and patients less invasive treatment options for a range of serious heart diseases.
In September 2021, Abbott received FDA approval for its Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease. With this new device, Abbott expanded its Epic surgical valve platform.
Therefore, technological advancements are creating lucrative opportunities in the aortic valve replacement devices market.
South & Central America Aortic Valve Replacement Devices Market Overview
The South & Central America aortic valve replacement devices market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market in the region is expected to grow due to the surge in prevalence of aortic stenosis, initiatives undertaken by various government organizations to create awareness about valve replacement surgeries.
South & Central America Aortic Valve Replacement Devices Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Aortic Valve Replacement Devices Market Segmentation
The South & Central America aortic valve replacement devices market is segmented into product, surgery, end user, and country.
Based on product, the South & Central America aortic valve replacement devices market is segmented into sutureless valve and mechanical valve. The sutureless valve held a larger South & Central America aortic valve replacement devices market share in 2022.
Based on surgery, the South & Central America aortic valve replacement devices market is segmented into minimally invasive surgery and open surgery. The minimally invasive surgery segment held a larger South & Central America aortic valve replacement devices market share in 2022.
Based on end user, the South & Central America aortic valve replacement devices market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment held the largest South & Central America aortic valve replacement devices market share in 2022.
Based on country, the South & Central America aortic valve replacement devices market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America aortic valve replacement devices market share in 2022.
Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, LivaNova Plc, Edwards Lifesciences Corp, Braile Biomedica Industry, Commerce and Representations Ltd, Artivion Inc, Venus MedTech HangZhou Inc, and Labcor Laboratorios Ltda. , are some of the leading companies operating in the aortic valve replacement devices market.